CAMPI, R. Et Al. 2023. Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?. 38th European Association of Urology Congress - 2023 , (Milan, Italy), 676.

CAMPI, R., AMPARORE, D., MARANDINO, L., BERTOLO, R., ERDEM, S., MUSELAERS, S., ... PAVAN, N.(2023). Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence? . 38th European Association of Urology Congress - 2023 (pp.676). Milan, Italy

CAMPI, RICCARDO Et Al. "Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?," 38th European Association of Urology Congress - 2023, Milan, Italy, 2023

CAMPI, RICCARDO Et Al. "Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?." 38th European Association of Urology Congress - 2023 , Milan, Italy, pp.676, 2023

CAMPI, R. Et Al. (2023) . "Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?." 38th European Association of Urology Congress - 2023 , Milan, Italy, p.676.

@conferencepaper{conferencepaper, author={RICCARDO CAMPI Et Al. }, title={Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?}, congress name={38th European Association of Urology Congress - 2023}, city={Milan}, country={Italy}, year={2023}, pages={676} }